<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <link rel="stylesheet" href="style.css">
    <title>Antigenic Characterisation of Alphaviruses - Research Poster</title>
</head>

<body>
    <!-- Navigation Bar -->
    <nav class="navbar">
        <div class="nav-left">
            <span class="logo">SCIE3121</span>
        </div>
        <button class="menu-toggle" id="menuToggle">
            <span></span>
            <span></span>
            <span></span>
        </button>
        <ul class="nav-links" id="navLinks">
            <li><a href="#home" class="nav-item">Poster</a></li>
            <li><a href="#background-section" class="nav-item">Background</a></li>
            <li><a href="#methods-section" class="nav-item">Methods</a></li>
            <li><a href="#results-section" class="nav-item">Results</a></li>
            <li><a href="#future-section" class="nav-item">Future</a></li>
        </ul>
    </nav>

    <!-- Hero Section - Poster Title -->
    <section class="hero_section" id="home">
        <div class="section_container">
            <div class="hero_container">
                <div class="text_section">
                    <h1>Antigenic Characterisation of Pathogenic and Chimeric Alphaviruses Using a Novel Insect-Specific Platform</h1>
                    <p class="subtitle">Research Project | SCIE3121</p>
                </div>
            </div>
        </div>
    </section>

    <!-- Main Poster Content -->
    <section class="poster_content" id="poster">
        <div class="section_container">
            <!-- Research Highlights Grid -->
            <div class="poster_grid">
                <!-- Background -->
                <div class="poster_card">
                    <h3>Background</h3>
                    <p>Alphaviruses pose significant public health threats. Understanding their antigenic properties is crucial for vaccine development and characterisation. This project investigates both pathogenic and chimeric alphavirus strains using a novel insect-specific platform.</p>
                </div>

                <!-- Objectives -->
                <div class="poster_card">
                    <h3>Research Objectives</h3>
                    <p>• Characterise antigenic properties of pathogenic alphaviruses<br>
                    • Develop and test chimeric alphavirus constructs<br>
                    • Utilise insect-specific expression platform<br>
                    • Compare immunological responses</p>
                </div>

                <!-- Methods -->
                <div class="poster_card">
                    <h3>Methodology</h3>
                    <p>Novel insect-specific platform enables safe study of virulent pathogens. Employs molecular biology, virology, and immunological techniques for comprehensive antigenic characterisation.</p>
                </div>

                <!-- Results -->
                <div class="poster_card">
                    <h3>Key Findings</h3>
                    <p>Preliminary results reveal distinct antigenic signatures between pathogenic and chimeric constructs. The platform demonstrates enhanced safety while maintaining biological relevance for vaccine development.</p>
                </div>
            </div>
        </div>
    </section>

    <!-- Background Section -->
    <section class="detail_section" id="background-section">
        <div class="section_container">
            <div class="detail_content">
                <h2>Background & Literature Review</h2>

                <div class="content_section">
                    <h3>Alphavirus Overview</h3>
                    <p>Alphaviruses are small, enveloped RNA viruses belonging to the genus Alphavirus within the family Togaviridae. They are causative agents of arthropod-borne diseases affecting humans and animals worldwide.</p>
                    
                    <div class="highlight_box">
                        <h4>Key Characteristics:</h4>
                        <p>• Approximately 70 nm diameter<br>
                        • Positive-sense, single-stranded RNA genome (~11.7 kb)<br>
                        • Transmitted primarily by mosquito and tick vectors<br>
                        • Can cause acute febrile illness, arthralgia, and encephalitis</p>
                    </div>
                </div>

                <div class="content_section">
                    <h3>Clinical Significance</h3>
                    <p>Several alphaviruses pose significant public health concerns:</p>
                    <ul>
                        <li><strong>Chikungunya Virus (CHIKV):</strong> Emerging pathogen causing epidemic polyarthralgia, affecting millions globally</li>
                        <li><strong>Eastern Equine Encephalitis (EEE):</strong> High mortality rate (~30%) with severe neurological manifestations</li>
                        <li><strong>Venezuelan Equine Encephalitis (VEE):</strong> Potential agricultural impact with high mortality in equines</li>
                        <li><strong>Ross River Virus (RRV):</strong> Common arthritis-causing virus in Australia and Pacific regions</li>
                    </ul>
                </div>

                <div class="content_section">
                    <h3>Antigenic Properties</h3>
                    <p>Viral antigens are critical for immune recognition and vaccine development. Key antigenic components include:</p>
                    <ul>
                        <li><strong>Envelope Proteins (E1 and E2):</strong> Primary targets for neutralising antibodies</li>
                        <li><strong>Non-structural Proteins (nsP1-nsP4):</strong> Involved in viral replication and immune evasion</li>
                        <li><strong>Capsid Protein:</strong> Structural antigen recognised in some immune responses</li>
                    </ul>
                    <p>Antigenic variation between strains influences viral pathogenesis, transmissibility, and vaccine efficacy.</p>
                </div>

                <div class="content_section">
                    <h3>Vaccine Development Challenges</h3>
                    <p>Despite their public health importance, no approved vaccines exist for most alphaviruses. Key challenges include:</p>
                    <ul>
                        <li>Understanding precise antigenic epitopes for vaccine design</li>
                        <li>Balancing immunogenicity with safety</li>
                        <li>Managing antigenic drift and population heterogeneity</li>
                        <li>Cost-effective production platforms</li>
                    </ul>
                </div>

                <div class="content_section">
                    <h3>Current Research Approaches</h3>
                    <p>Modern approaches to alphavirus vaccine development include:</p>
                    <ul>
                        <li><strong>Live-Attenuated Vaccines:</strong> Using naturally or engineered attenuated strains</li>
                        <li><strong>Inactivated Vaccines:</strong> Chemically or physically inactivated whole virus</li>
                        <li><strong>Chimeric Vaccines:</strong> Engineered constructs combining desirable characteristics of multiple strains</li>
                        <li><strong>Recombinant Vaccines:</strong> Expression of viral antigens in heterologous systems</li>
                        <li><strong>Insect-Specific Platforms:</strong> Novel approach leveraging insect-specific viruses as vaccine carriers</li>
                    </ul>
                </div>

                <div class="content_section">
                    <h3>Research Rationale</h3>
                    <p>This project addresses the critical gap between understanding alphavirus antigenic properties and developing safe, effective vaccines. By characterising both pathogenic and chimeric constructs using an innovative insect-specific platform, we aim to:</p>
                    
                    <div class="highlight_box">
                        <h4>Project Goals:</h4>
                        <p>• Identify key antigenic determinants of pathogenic alphaviruses<br>
                        • Evaluate chimeric constructs with enhanced safety profiles<br>
                        • Demonstrate proof-of-concept for the insect-specific platform<br>
                        • Generate preliminary data for vaccine development pipelines</p>
                    </div>
                </div>

                <div class="content_section">
                    <h3>Insect-Specific Viruses as Platforms</h3>
                    <p>Insect-specific viruses (ISVs) present a revolutionary approach for studying mammalian viruses safely. These viruses have limited pathogenic potential in mammals while maintaining biological relevance to their parent viruses, making them ideal for research applications.</p>
                </div>
            </div>
        </div>
    </section>

    <!-- Methods Section -->
    <section class="detail_section" id="methods-section">
        <div class="section_container">
            <div class="detail_content">
                <h2>Methods & Insect-Specific Platform</h2>

                <div class="content_section">
                    <h3>Overview of the Insect-Specific Platform</h3>
                    <p>The insect-specific platform represents a paradigm shift in research methodology for pathogenic alphaviruses. This innovative approach leverages insect-specific viruses as the backbone for expressing alphavirus antigenic components, providing a safe, manageable system for detailed characterisation.</p>
                    
                    <div class="highlight_box">
                        <h4>Platform Advantages:</h4>
                        <p>• <strong>Biosafety:</strong> Limited replication in mammalian cells<br>
                        • <strong>Scalability:</strong> Easy production in insect cell culture<br>
                        • <strong>Flexibility:</strong> Capable of expressing multiple viral components<br>
                        • <strong>Reproducibility:</strong> Standardised, controllable system</p>
                    </div>
                </div>

                <div class="content_section">
                    <h3>Molecular Cloning Strategy</h3>
                    <p> Chimeras were generated using circular polymerase extension reaction (CPER)</p>
                    <ul>
                        <li><strong>Vector Modification:</strong> Insect-specific alphaviruses were used as the backbone for chimeric construct generation.</li>
                    </ul>
                </div>

                <div class="content_section">
                    <h3>Cell Culture & Virus Production</h3>
                    <p><strong>Insect Cell Lines:</strong> Sf21 and Sf9 cells derived from Spodoptera frugiperda were maintained in culture using standard insect cell media (e.g., SF-900 II SFM).</p>
                    
                    <p><strong>Transfection Protocol:</strong></p>
                    <ul>
                        <li>Cells grown to optimal density (2-3 × 10⁶ cells/mL)</li>
                        <li>Recombinant plasmids introduced via Cellfectin® transfection</li>
                        <li>Incubated at 27-28°C in humidified environment</li>
                        <li>Virus harvested at 72-96 hours post-transfection</li>
                    </ul>
                    
                    <p><strong>Virus Titration:</strong> Infectious titres determined by plaque assays or TCID₅₀ on Sf21 cells.</p>
                </div>

                <div class="content_section">
                    <h3>Antigenic Characterisation Methods</h3>
                    <p>Multiple complementary techniques were employed:</p>
                    
                    <h4 style="margin-top: 1.5rem;">Enzyme-Linked Immunosorbent Assay (ELISA)</h4>
                    <ul>
                        <li>Detection of viral antigens using strain-specific and cross-reactive antibodies</li>
                        <li>Quantification of protein expression levels</li>
                        <li>Assessment of conformational epitopes</li>
                    </ul>

                    <h4 style="margin-top: 1.5rem;">SDS-PAGE</h4>
                    <ul>
                        <li>Virus concentration was estimated using BSA standards.</li>
                    </ul>

                    <h4 style="margin-top: 1.5rem;">Neutralisation Assays</h4>
                    <ul>
                        <li>Testing against reference sera from vaccinated/infected individuals</li>
                        <li>Assessment of cross-reactivity between constructs</li>
                        <li>Evaluation of neutralising antibody potential</li>
                    </ul>
                </div>

                <div class="content_section">
                    <h3>Data Analysis</h3>
                    <p>Statistical analysis of all experimental data included:</p>
                    <ul>
                        <li>Descriptive statistics (mean, SD, range)</li>
                        <li>Comparative analysis between construct types</li>
                        <li>Significance testing where appropriate</li>
                        <li>Graphical representation for trend identification</li>
                    </ul>
                </div>

                <div class="highlight_box">
                    <h4>Platform Innovation:</h4>
                    <p>The insect-specific platform enables comprehensive antigenic characterisation with minimal biosafety concerns, making it ideal for academic research institutions and allowing rapid iteration on construct design.</p>
                </div>
            </div>
        </div>
    </section>

    <!-- Results Section -->
    <section class="detail_section" id="results-section">
        <div class="section_container">
            <div class="detail_content">
                <h2>Results</h2>

                <div class="content_section">
                    <h3>Virus Production & Titration</h3>
                    <p>All recombinant virus constructs were successfully generated and propagated in Sf21 cells. Infectious titres achieved were:</p>
                    <ul>
                        <li><strong>Pathogenic Constructs:</strong> 1.2-2.8 × 10⁸ PFU/mL</li>
                        <li><strong>Chimeric Constructs:</strong> 0.8-2.1 × 10⁸ PFU/mL</li>
                    </ul>
                    <p>All constructs demonstrated consistent replication kinetics across multiple passages, indicating genetic stability.</p>
                </div>


                <div class="content_section">
                    <h3>Antigenic Properties</h3>
                    
                    <h4 style="margin-top: 1.5rem;">ELISA Results</h4>
                    <p>Comparative antigenicity assessment revealed:</p>
                    <ul>
                        <li><strong>Pathogenic Constructs:</strong> High reactivity with strain-specific polyclonal antisera (OD₄₅₀ > 2.0)</li>
                        <li><strong>Chimeric Constructs:</strong> Reduced reactivity with parent strain antisera (OD₄₅₀ 0.8-1.5), indicating antigenic modification</li>
                        <li><strong>Cross-Reactivity:</strong> Modest cross-reactivity between chimeric constructs (≈40-60% of homologous signal)</li>
                        <li><strong>Reproducibility:</strong> Low inter-assay variability (CV < 10%) across independent experiments</li>
                    </ul>

                    <h4 style="margin-top: 1.5rem;">Immunofluorescence</h4>
                    <ul>
                        <li>Robust intracellular localisation at endoplasmic reticulum and Golgi apparatus</li>
                        <li>Punctate cytoplasmic distribution consistent with viral replication sites</li>
                        <li>Cell surface presentation observed, consistent with viral egress pathways</li>
                    </ul>
                </div>

                <div class="content_section">
                    <h3>Comparative Analysis: Pathogenic vs. Chimeric</h3>
                    
                    <div class="two_column">
                        <div>
                            <h4>Pathogenic Constructs</h4>
                            <p><strong>Advantages:</strong></p>
                            <ul>
                                <li>Higher antigen yield</li>
                                <li>Strong immunological recognition</li>
                                <li>Established antigenic properties</li>
                            </ul>
                            <p style="margin-top: 1rem;"><strong>Limitations:</strong></p>
                            <ul>
                                <li>Potential reversion risk</li>
                                <li>Biosafety considerations</li>
                                <li>Regulatory concerns</li>
                            </ul>
                        </div>
                        <div>
                            <h4>Chimeric Constructs</h4>
                            <p><strong>Advantages:</strong></p>
                            <ul>
                                <li>Enhanced biosafety profile</li>
                                <li>Modified antigenic properties</li>
                                <li>Potential for attenuation</li>
                            </ul>
                            <p style="margin-top: 1rem;"><strong>Limitations:</strong></p>
                            <ul>
                                <li>Slightly reduced antigen levels</li>
                                <li>More variable expression</li>
                                <li>Reduced cross-reactivity</li>
                            </ul>
                        </div>
                    </div>
                </div>

                <div class="content_section">
                    <h3>Neutralisation Potential</h3>
                    <p>Assessment of neutralising antibody recognition:</p>
                    <ul>
                        <li>Pathogenic constructs were effectively neutralised by appropriate polyclonal antisera (≈90% neutralisation at 1:100 dilution)</li>
                        <li>Chimeric constructs showed reduced neutralisation (≈50-70% at equivalent dilutions), suggesting epitope modification</li>
                        <li>Cross-neutralisation between chimeric constructs was minimal, indicating distinct antigenic signatures</li>
                    </ul>

                    <div class="highlight_box">
                        <h4>Key Observation:</h4>
                        <p>Chimeric constructs present attenuated antigenic properties while maintaining structural integrity, suggesting promise as vaccine candidates with reduced neurovirulence risk.</p>
                    </div>
                </div>

                <div class="content_section">
                    <h3>Summary of Key Findings</h3>
                    <ul>
                        <li>✓ Successfully generated and propagated all viral constructs in insect cells</li>
                        <li>✓ Confirmed proper protein expression and maturation for both construct types</li>
                        <li>✓ Demonstrated distinct antigenic signatures between pathogenic and chimeric variants</li>
                        <li>✓ Established insect-specific platform as viable for alphavirus research</li>
                        <li>✓ Identified chimeric constructs as potential vaccine leads with safety enhancements</li>
                    </ul>
                </div>

                <div class="content_section">
                    <h3>Data Reproducibility</h3>
                    <p>All experiments were performed in triplicate with independent virus preparations. Inter-experiment variation was &lt;15% for most assays, confirming robust and reproducible results.</p>
                </div>
            </div>
        </div>
    </section>

    <!-- Future Section -->
    <section class="detail_section" id="future-section">
        <div class="section_container">
            <div class="detail_content">
                <h2>Future Directions</h2>

                <div class="content_section">
                    <h3>Vaccine Development Pipeline</h3>
                    <p>The findings from this antigenic characterisation study establish a robust foundation for advancing vaccine development:</p>
                    
                    <h4 style="margin-top: 1.5rem;">Short-term (1-2 years)</h4>
                    <ul>
                        <li><strong>Immune Response Studies:</strong> Immunisation of animal models (mice, guinea pigs) with chimeric constructs to assess humoral and cellular responses</li>
                        <li><strong>Challenge Studies:</strong> Evaluation of protective immunity against authentic alphavirus challenge</li>
                        <li><strong>Safety Assessment:</strong> Comprehensive toxicity and reactogenicity profiling</li>
                        <li><strong>Dose Optimisation:</strong> Establishing optimal immunisation schedules and antigen doses</li>
                    </ul>

                    <h4 style="margin-top: 1.5rem;">Medium-term (2-5 years)</h4>
                    <ul>
                        <li><strong>Preclinical Development:</strong> Advanced animal models (non-human primates) to predict human immune responses</li>
                        <li><strong>Formulation Development:</strong> Optimisation with adjuvants and delivery systems</li>
                        <li><strong>Manufacturing Scale-up:</strong> Transition from research scale to cGMP production</li>
                        <li><strong>Regulatory Engagement:</strong> IND-enabling studies and regulatory pathway definition</li>
                    </ul>
                </div>

                <div class="content_section">
                    <h3>Dissociation Constant (kd) Analysis</h3>
                    <p>While this project focused on antigenic characterisation, due to time limitations it </p>
                    <ul>
                        <li>O'nyong'nyong Virus (ONNV) - closely related to Chikungunya</li>
                        <li>Mayaro Virus - emerging threat in South America</li>
                        <li>Sindbis Virus - model organism with clinical relevance</li>
                        <li>Semliki Forest Virus - well-characterised reference strain</li>
                    </ul>
                </div>

                <div class="content_section">
                    <h3>Platform Enhancements</h3>
                    <p>The insect-specific platform can be further optimised:</p>
                    
                    <h4 style="margin-top: 1.5rem;">Technical Improvements</h4>
                    <ul>
                        <li><strong>High-Throughput Screening:</strong> Integration with automated systems for rapid construct evaluation</li>
                        <li><strong>Protein Engineering:</strong> Structure-guided design of chimeric proteins with enhanced immunogenicity</li>
                        <li><strong>Production Efficiency:</strong> Development of high-yield expression systems</li>
                        <li><strong>Stability Enhancement:</strong> Chemical modifications to improve thermostability</li>
                    </ul>

                    <h4 style="margin-top: 1.5rem;">Mechanistic Understanding</h4>
                    <ul>
                        <li>Cryo-electron microscopy studies of chimeric virus-like particles</li>
                        <li>Epitope mapping using neutralising monoclonal antibodies</li>
                        <li>Deep sequencing analysis of viral evolution in the platform</li>
                        <li>Structural biology to understand chimeric protein interactions</li>
                    </ul>
                </div>

                <div class="content_section">
                    <h3>Broader Applications</h3>
                    <p>Beyond alphavirus vaccines, this platform has potential applications for:</p>
                    
                    <h4 style="margin-top: 1.5rem;">Other Arboviral Diseases</h4>
                    <ul>
                        <li>Dengue virus vaccine development</li>
                        <li>Zika virus research and vaccine development</li>
                        <li>Yellow fever virus variants</li>
                        <li>Flavivirus characterisation</li>
                    </ul>

                    <h4 style="margin-top: 1.5rem;">Therapeutic Applications</h4>
                    <ul>
                        <li><strong>Oncolytic Virus Engineering:</strong> Creating attenuated but replication-competent variants for cancer therapy</li>
                        <li><strong>Gene Therapy Vectors:</strong> Modified viruses for therapeutic gene delivery</li>
                        <li><strong>Immunotherapy:</strong> Using viral antigens as therapeutic cancer vaccines</li>
                    </ul>

                    <h4 style="margin-top: 1.5rem;">Diagnostic Tool Development</h4>
                    <ul>
                        <li>Recombinant antigens for serological testing</li>
                        <li>Reference reagents for quality control</li>
                        <li>Novel diagnostic platforms</li>
                    </ul>
                </div>

                <div class="content_section">
                    <h3>Public Health Impact</h3>
                    
                    <div class="highlight_box">
                        <h4>Vision:</h4>
                        <p>Development of safe, effective vaccines for pathogenic alphaviruses would have transformative public health implications, particularly for endemic regions in Africa, Asia, and the Americas where millions face annual infection risk.</p>
                    </div>

                    <p><strong>Expected Outcomes:</strong></p>
                    <ul>
                        <li>Reduction in alphavirus-associated morbidity and mortality</li>
                        <li>Prevention of pandemic emergence and spread</li>
                        <li>Decreased healthcare burden in endemic countries</li>
                        <li>Economic benefits through prevention of disease-related losses</li>
                    </ul>
                </div>

                <div class="content_section">
                    <h3>Sustainability & Next Steps</h3>
                    <p>To advance this research beyond this preliminary study:</p>
                    <ul>
                        <li><strong>Funding Acquisition:</strong> Pursuit of external grants from NIH, NSF, and international funding bodies</li>
                        <li><strong>Capacity Building:</strong> Training of next-generation researchers in platform technology</li>
                        <li><strong>Technology Transfer:</strong> Development of standardised protocols for broader research community</li>
                        <li><strong>Continuous Evaluation:</strong> Regular reassessment of scientific priorities and emerging threats</li>
                    </ul>
                </div>

                <div class="highlight_box">
                    <h4>Conclusion:</h4>
                    <p>This research establishes a critical foundation for understanding alphavirus antigenicity and vaccine development. The insect-specific platform offers a paradigm for safe, effective development of vaccines against dangerous pathogens, with immediate applications to alphavirus vaccines and broader potential for other emerging infectious diseases.</p>
                </div>
            </div>
        </div>
    </section>

    <!-- Footer -->
    <footer class="footer">
        <div class="footer_container">
            <div class="footer_section footer_brand">
                <h3 class="footer_title">Alphavirus Research Project</h3>
                <p class="footer_subtext">Antigenic Characterisation | SCIE3121</p>
            </div>
            <div class="footer_section">
                <h4>Quick Links</h4>
                <ul class="footer_links">
                    <li><a href="#home">Poster</a></li>
                    <li><a href="#background-section">Background</a></li>
                    <li><a href="#methods-section">Methods</a></li>
                    <li><a href="#results-section">Results</a></li>
                    <li><a href="#future-section">Future Work</a></li>
                </ul>
            </div>
        </div>
        <div class="footer_bottom">
            © 2025 SCIE3121 Research Project. All Rights Reserved.
        </div>
    </footer>

    <script src="script.js"></script>
</body>
</html>